Sign In
Last checked at 
14 Apr 2011 16:04
ο»Ώ
Annual Information Update
Β
LONDON, 14 April 2011. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.
Β
Stock Exchange Announcements
Β
Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:
Β
Date of Announcement | Headline of Announcement |
13/04/2011 | Director/PDMR Shareholding |
11/04/2011 | Total Voting Rights |
11/04/2011 | Blocklisting Interim Review |
04/04/2011 | Director/PDMR Shareholding |
18/03/2011 | Director/PDMR Shareholding |
16/03/2011 | Preliminary Results |
02/03/2011 | Total Voting Rights |
08/02/2011 | Total Voting Rights |
03/02/2011 | Holding(s) in Company |
24/01/2011 | Appointments |
12/01/2011 | Total Voting Rights |
12/01/2011 | Director/PDMR Shareholding |
10/01/2011 | Director/PDMR Shareholding |
10/01/2011 | Director/PDMR Shareholding |
05/01/2011 | Total Voting Rights |
16/12/2010 | Director/PDMR Shareholding |
06/12/2010 | Director/PDMR Shareholding |
01/12/2010 | Director/PDMR Shareholding |
12/11/2010 | Interim Management Statement |
09/11/2010 | Director/PDMR Shareholding |
05/11/2010 | Total Voting Rights |
04/11/2010 | Director/PDMR Shareholding |
02/11/2010 | Director/PDMR Shareholding |
29/10/2010 | Acquisition |
18/10/2010 | Product Update |
15/10/2010 | Block Listing for Share Schemes |
04/10/2010 | Total Voting Rights |
04/10/2010 | Blocklisting Interim Review |
01/10/2010 | Company Update |
06/09/2010 | Total Voting Rights |
26/08/2010 | Interim Results |
04/08/2010 | Voting Rights and Capital |
02/08/2010 | Annual Information Update |
Β
All of the above announcements were also made by the Company via the NasdaqDubai stock exchange CANDI system. These announcements may be viewed and downloaded from the NasdaqDubai website (www.candi.nasdaq.com).
Β
Documents filed with the Financial Services Authority
Β
The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months. These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.
Β
Date | Document |
6 April 2011 | Annual Report and Accounts 2010 |
6 April 2011 | Notice of 2011 Annual General Meeting |
14 April 2011 | Proxy forms for the 2011 Annual General Meeting |
Β
Documents filed with Companies House
Β
The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below.
Β
Date Filed | Form | Description |
08/02/2011 | SH01 | 31/01/11 Statement of Capital GBP 19356098 |
14/01/2011 | SH01 | 31/12/10 Statement of Capital GBP 19351698 |
05/01/2011 | SH01 | 30/11/10 Statement of Capital GBP 19344848 |
11/11/2010 | SH01 | 31/10/10 Statement of Capital GBP 19340139 |
18/10/2010 | SH01 | 30/09/10 Statement of Capital GBP 19338739 |
09/09/2010 | AR01 | 08/09/10 Full List |
02/09/2010 | CH01 | Director's Change of Particulars / Samih Darwazah / 01/09/2010 |
02/09/2010 | CH01 | Director's Change of Particulars / Ali Al Husry / 01/09/2010 |
02/09/2010 | CH01 | Director's Change of Particulars / Mazen Samih Darwazeh / 01/09/2010 |
02/09/2010 | CH01 | Director's Change of Particulars / Ronald Lane Goode / 01/09/2010 |
01/09/2010 | CH01 | Director's Change of Particulars / Michael Richard Dwyer Ashton / 01/09/2010 |
01/09/2010 | CH01 | Director's Change of Particulars / Said Samih Darwazah / 01/09/2010 |
01/09/2010 | CH01 | Director's Change of Particulars / Breffni John Byrne / 01/09/2010 |
01/09/2010 | CH01 | Director's Change of Particulars / Sir David Rowe Ham / 01/09/2010 |
01/09/2010 | CH03 | Secretary's Change of Particulars / Henry James Knowles / 01/09/2010 |
23/08/2010 | SH01 | 30/06/10 Statement of Capital GBP 19336649 |
Β
Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk.
Β
Further Information
Β
Further information about Hikma Pharmaceuticals PLC can be found at our website www.hikma.com. Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.
Β
Β
Henry Knowles
Company Secretary
14 April 2011
Β
- ENDS -
Β
Β
Enquiries:
Β
Hikma Pharmaceuticals PLC | Β | |
Henry Knowles Company Secretary Β | +44 20 7399 2670 | |
Susan Ringdal Investor Relations Director | +44 20 7399 2670 Β | |
| Financial Dynamics | Β | |
Ben Atwell/ Julia Phillips | +44 20 7269 7242 | |
Jonathan Birt/ Matthew Cole | ||
Β
Β
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million). For news and other information, please visit www.hikma.com.
Β
Follow the stocks
